Early Detection Biomarkers for Mesothelioma Among Asbestos and Vermiculite Exposed Populations
OBJECTIVES:
- Identify patients with known asbestos exposure at early stages of disease development
(i.e., indolent premalignant pleural plaques and fibrosis vs malignant pleural
mesothelioma).
- Determine the expression levels of tumor-associated proteins in these patients.
- Analyze samples of serum and pleural effusions obtained from these patients.
- Determine the proteomic profile of samples obtained from these patients.
- Determine the molecular mechanisms associated with the regulation of the extracellular
matrix microenvironment proteins (e.g., osteonectin, intelectin, or matrix
metalloproteins) involved in disease onset and progression.
OUTLINE: This is a multicenter study.
Patients undergo collection of body cavity fluid, including pleural effusion, and blood.
Specimens, including fresh frozen malignant pleural mesothelioma tumor tissue, if available,
are analyzed for proteomic profile, gene expression profile, and tumor-associated protein
expression levels.
PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.
Observational
Observational Model: Case Control, Time Perspective: Prospective
Identification of potential drug targets for therapeutic strategies to treat asbestos fiber-related diseases
At time of analysis
No
Anil Wali, PhD
Study Chair
Barbara Ann Karmanos Cancer Institute
United States: Federal Government
CDR0000518348
NCT00897247
January 2007
Name | Location |
---|---|
Barbara Ann Karmanos Cancer Institute | Detroit, Michigan 48201 |